PDCD1 and uveitis: As PD-1 inhibitors have an enhanced effect against melanocytes, they are proposed to be more likely to cause sensorineural hearing loss, which is usually accompanied by damage to the melanocytes of the uvea (uveitis) and the melanocytes of the skin (vitiligo) [33].